Page last updated: 2024-11-11

n-caproylsphingosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(hexanoyl)sphing-4-enine : An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5702613
CHEMBL ID224877
CHEBI ID63867
SCHEMBL ID13587660
MeSH IDM0267117

Synonyms (56)

Synonym
124753-97-5
n-(2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)hexanamide
nsc-655091
SMP2_000293
n-caproylsphingosine
c(6)-ceramide
n-hexanoylsphingosine
c6-ceramide
HSCI1_000109
n-hexanoyl-d-sphingosine, >=98% (tlc), synthetic
6cm ,
n-((e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl)hexanamide
c6 ceramide
NCGC00163521-01
n-hexanoyl-d-erythro-sphingosine
n-hexanoylspingosine
(2s,3r,4e)-ceramide
chebi:63867 ,
CHEMBL224877
n-[(e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]hexanamide
038753e78j ,
unii-038753e78j
n-hexanoyl-d-eythro-spingosine
ceramid 6
nsc 655091
cer(d18:1/6:0)
d-erythro-n-hexanoylsphingosine
n-(hexanoyl)sphing-4-enine
c6-cer
caprooyl sphingosine [inci]
n-caproyl-c18-sphingosine
hexanamide, n-((1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl)-
hexanamide, n-((1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)-
hexanamide, n-(2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl)-, (r-(r*,s*-(e)))-
caprooyl sphingosine
CCG-208164
SCHEMBL13587660
c-6 ceramide
HMS3649E07
6-hexanoyl-d-erythro-sphingosine
sr-05000002364
SR-05000002364-2
AS-73035
n-[(2s,3r,4e)-1,3-dihydroxyoctadec-4-en-2-yl]hexanamide
c6 ceramide (d18:1/6:0), n-hexanoyl-d-erythro-sphingosine, powder
n-((2s,3r,e)-1,3-dihydroxyoctadec-4-en-2-yl)hexanamide
n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)heptadec-3-en-1-yl]hexanamide
DTXSID90924923
Q27132875
SR-05000002364-3
hexanamide, n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-
F82077
AKOS037647257
HY-19542
CS-0015638
BP-28809

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Based upon previous work demonstrating that nanoliposome C6-ceramide (LipC6) not only induces HCC apoptosis but also prevents HCC-induced immune tolerance, we now investigate the potential of LipC6 in combination with ICB in HCC treatment."( Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.
Fox, T; Illendula, A; Kaifi, JT; Kester, M; Kim, SH; Kimchi, ET; Li, G; Qi, X; Snyder, H; Staveley-O'Carroll, KF; Wu, F, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The decreased bioavailability of NO is likely to favor a proatherogenic role of ceramide."( Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase.
Burkhardt, C; Förstermann, U; Huwiler, A; Junk, P; Li, H; Pfeilschifter, J; Wallerath, T, 2002
)
0.31
" We conclude that C6-Cer complexed to CholPC increased the bioavailability of the short-chain ceramide for cells, and potentiated its effects in comparison to solvent-dissolved C6-Cer."( Complexation of c6-ceramide with cholesteryl phosphocholine - a potent solvent-free ceramide delivery formulation for cells in culture.
Långvik, O; Lönnfors, M; Pulli, I; Slotte, JP; Sukumaran, P; Törnquist, K, 2013
)
0.39
" Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to the pronounced hydrophobicity of Cer."( Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations.
Gu, X; Hill, RA; Hosain, SB; Khiste, SK; Liu, YY; Liu, Z; Nazzal, S; Roy, KR; Uddin, MB, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acylsphingosineThe parent compounds of the ceramide family, composed of sphingosine having an unspecified fatty acyl group attached to the nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency354.81300.010039.53711,122.0200AID1479
DNA polymerase kappa isoform 1Homo sapiens (human)Potency2.66790.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID526957Metabolic stability in human MCF7 cells assessed as C24:1-ceramide levels at 20 uM after 24 hrs by LC-MS/MS analysis relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526967Metabolic stability in human MCF7 cells assessed as cellular ceramide levels at 10 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID401377Toxicity against Ulva conglobata at 50 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID393057Cytotoxicity against human SupT1 cells after 24 hrs by CellTiter-Blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Ceramides: branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency.
AID526955Metabolic stability in human MCF7 cells assessed as C14-ceramide levels at 20 uM after 24 hrs by LC-MS/MS analysis relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526783Metabolic stability in human MCF7 cells assessed as endogenous ceramide levels at 20 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID284353Cytotoxicity against human A549 cells in presence of 10% FBS after 72 hrs by MTT test2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Solid-phase synthesis of a combinatorial library of dihydroceramide analogues and its activity in human alveolar epithelial cells.
AID284354Cytotoxicity against human A549 cells after 72 hrs by MTT test2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Solid-phase synthesis of a combinatorial library of dihydroceramide analogues and its activity in human alveolar epithelial cells.
AID284352Cytotoxicity against human A549 cells upto 1 mM in presence of <=5% FBS after 72 hrs by MTT test2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Solid-phase synthesis of a combinatorial library of dihydroceramide analogues and its activity in human alveolar epithelial cells.
AID526956Metabolic stability in human MCF7 cells assessed as C16-ceramide levels at 20 uM after 24 hrs by LC-MS/MS analysis relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID526958Metabolic stability in human MCF7 cells assessed as C24-ceramide levels at 20 uM after 24 hrs by LC-MS/MS analysis relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526782Metabolic stability in human MCF7 cells assessed as cellular sphingosine-1-phosphate levels at 20 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526954Metabolic stability in human MCF7 cells assessed as C18-ceramide levels at 20 uM after 24 hrs by LC-MS/MS analysis relative to control2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526966Metabolic stability in human MCF7 cells assessed as cellular ceramide levels at 10 uM after up to 5 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526784Metabolic stability in human MCF7 cells assessed as endogenous sphingosine levels at 20 uM after 24 hrs by LC-MS/MS analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
AID526773Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (174)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's32 (18.39)18.2507
2000's75 (43.10)29.6817
2010's55 (31.61)24.3611
2020's12 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.37 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other173 (98.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]